Press release
Heart failure with Reduced Ejection Fraction Market to Witness Promising Upswing by 2032, DelveInsight Forecasts
DelveInsight's "Heart failure with Reduced Ejection Fraction Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Heart failure with Reduced Ejection Fraction, historical and forecasted epidemiology as well as the Heart failure with Reduced Ejection Fraction market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Heart failure with Reduced Ejection Fraction market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Heart failure with Reduced Ejection Fraction market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Heart failure with Reduced Ejection Fraction Market Forecast
https://www.delveinsight.com/sample-request/heart-failure-hf-with-reduced-ejection-fraction-hfref-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Heart failure with Reduced Ejection Fraction Market Report:
• The Heart failure with Reduced Ejection Fraction market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In December 2024, Cytokinetics, Incorporated (Nasdaq: CYTK) announced the initiation of enrollment for COMET-HF (Confirmation of Omecamtiv Mecarbil Efficacy Trial in Heart Failure), a Phase 3 confirmatory trial evaluating omecamtiv mecarbil in patients with symptomatic heart failure (HF) and severely reduced ejection fraction. Omecamtiv mecarbil, a novel investigational selective cardiac myosin activator, is being developed as a potential treatment for this condition. The COMET-HF trial is being conducted in collaboration with the Duke Clinical Research Institute (DCRI), a renowned academic research organization.
• In August 2024, Eli Lilly and Company (NYSE: LLY) reported positive topline results from the SUMMIT phase 3 trial evaluating tirzepatide injection (5 mg, 10 mg, and 15 mg) in adults with heart failure with preserved ejection fraction (HFpEF) and obesity. Tirzepatide achieved statistically significant improvements in both primary endpoints, including a reduced risk of heart failure outcomes (composite endpoint) and enhanced heart failure symptoms and physical limitations, as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS), compared to placebo.
• Heart failure with reduced ejection fraction (HFrEF) occurs when the Ejection Fraction is less than or equal to 40%
• The Heart failure with Reduced Ejection Fraction etiology states that multiple conditions can cause HF, including systemic diseases, a wide range of cardiac conditions, and some hereditary defects
• Heart Failure is a significant public health problem with a prevalence of over 5.8 to 6.5 million in the United States
• According to data from the Framingham Heart Study, the prevalence of heart failure rises with age, with 8 men per 1000 men aged 50 to 59 years and 66 men per 1000 men aged 80 to 89 years, and comparable numbers for women (8 and 79 per 1000)
• Key Heart failure with Reduced Ejection Fraction Companies: Ionis Pharmaceuticals, Cytokinetics, Salubris Biotherapeutics Inc, MYK-491, Stealth BioTherapeutics Inc., PhaseBio Pharmaceuticals Inc., AstraZeneca, Sardocor Corp., Berlin Cures GmbH, Innolife Co., Ltd., Bayer, Zensun Sci. & Tech. Co., Ltd., Olatec Therapeutics LLC., Intra-Cellular Therapies, Inc., Asklepios Biopharmaceutical, Inc., and others
• Key Heart failure with Reduced Ejection Fraction Therapies: IONIS-AGT-LRx, Omecamtiv mecarbil, and others
Heart failure with Reduced Ejection Fraction Overview
Heart failure with Reduced Ejection Fraction (HFrEF) is a condition where the heart's left ventricle loses its ability to contract effectively, resulting in a reduced ejection fraction (EF), which is the percentage of blood pumped out with each heartbeat. Normally, the heart pumps out about 55% to 70% of the blood in the left ventricle, but in HFrEF, this number drops below 40%. This leads to poor blood circulation, causing symptoms like shortness of breath, fatigue, and swelling. The condition can be caused by various factors, including heart attacks, high blood pressure, and certain diseases. Treatment focuses on managing symptoms and improving heart function through medications, lifestyle changes, and sometimes surgical interventions.
Get a Free sample for the Heart failure with Reduced Ejection Fraction Market Report
https://www.delveinsight.com/report-store/heart-failure-hf-with-reduced-ejection-fraction-hfref-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Heart failure with Reduced Ejection Fraction Market
The dynamics of the Heart failure with Reduced Ejection Fraction market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.
Heart failure with Reduced Ejection Fraction Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Heart failure with Reduced Ejection Fraction Epidemiology Segmentation:
The Heart failure with Reduced Ejection Fraction market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Heart failure with Reduced Ejection Fraction
• Prevalent Cases of Heart failure with Reduced Ejection Fraction by severity
• Gender-specific Prevalence of Heart failure with Reduced Ejection Fraction
• Diagnosed Cases of Episodic and Chronic Heart failure with Reduced Ejection Fraction
Download the report to understand which factors are driving Heart failure with Reduced Ejection Fraction epidemiology trends @ Heart failure with Reduced Ejection Fraction Epidemiological Insights
https://www.delveinsight.com/sample-request/heart-failure-hf-with-reduced-ejection-fraction-hfref-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Heart failure with Reduced Ejection Fraction Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Heart failure with Reduced Ejection Fraction market or expected to get launched during the study period. The analysis covers Heart failure with Reduced Ejection Fraction market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Heart failure with Reduced Ejection Fraction Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Heart failure with Reduced Ejection Fraction Therapies and Key Companies
• IONIS-AGT-LRx: Ionis Pharmaceuticals
• Omecamtiv mecarbil: Cytokinetics
To know more about Heart failure with Reduced Ejection Fraction treatment, visit @ Heart failure with Reduced Ejection Fraction Medications
https://www.delveinsight.com/sample-request/heart-failure-hf-with-reduced-ejection-fraction-hfref-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Heart failure with Reduced Ejection Fraction Market Drivers
• Rising prevalence of cardiovascular diseases, hypertension, diabetes, and ischemic heart disease globally
• Aging population increasing the overall heart failure patient pool
• Advancements in guideline-directed medical therapies, including novel drug classes and combination regimens
• Strong clinical evidence supporting improved outcomes, driving higher treatment adoption
• Increased awareness, early diagnosis, and improved access to cardiology care in developed markets
• Favorable reimbursement policies and inclusion of innovative therapies in treatment guidelines
Heart failure with Reduced Ejection Fraction Market Barriers
• High cost of newer therapies limiting affordability and access in price-sensitive regions
• Complex disease management requiring polypharmacy, impacting patient adherence
• Risk of adverse effects and contraindications in elderly and comorbid patients
• Underdiagnosis in early stages and delayed treatment initiation in low-resource settings
• Variability in treatment response across patient subgroups
• Regulatory and market access challenges for emerging therapies in certain geographies
Scope of the Heart failure with Reduced Ejection Fraction Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Heart failure with Reduced Ejection Fraction Companies: Ionis Pharmaceuticals, Cytokinetics, Salubris Biotherapeutics Inc, MYK-491, Stealth BioTherapeutics Inc., PhaseBio Pharmaceuticals Inc., AstraZeneca, Sardocor Corp., Berlin Cures GmbH, Innolife Co., Ltd., Bayer, Zensun Sci. & Tech. Co., Ltd., Olatec Therapeutics LLC., Intra-Cellular Therapies, Inc., Asklepios Biopharmaceutical, Inc., and others
• Key Heart failure with Reduced Ejection Fraction Therapies: IONIS-AGT-LRx, Omecamtiv mecarbil, and others
• Heart failure with Reduced Ejection Fraction Therapeutic Assessment: Heart failure with Reduced Ejection Fraction current marketed and Heart failure with Reduced Ejection Fraction emerging therapies
• Heart failure with Reduced Ejection Fraction Market Dynamics: Heart failure with Reduced Ejection Fraction market drivers and Heart failure with Reduced Ejection Fraction market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Heart failure with Reduced Ejection Fraction Unmet Needs, KOL's views, Analyst's views, Heart failure with Reduced Ejection Fraction Market Access and Reimbursement
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Heart failure with Reduced Ejection Fraction Market to Witness Promising Upswing by 2032, DelveInsight Forecasts here
News-ID: 4349804 • Views: …
More Releases from DelveInsight Business Research
Retinal Vein Occlusion Pipeline 2025: Therapies, MOA Insights, and Key Clinical …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Retinal Vein Occlusion pipeline constitutes 15+ key companies continuously working towards developing 15+ Retinal Vein Occlusion treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Retinal Vein Occlusion Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Retinal Vein…
HER2-Negative Breast Cancer Pipeline and Clinical Trial Analysis: 70+ Players, 7 …
DelveInsight's "HER2-Negative Breast Cancer Pipeline Insight" report delivers an extensive analysis of more than 70 companies and 75 pipeline candidates shaping the HER2-negative breast cancer research landscape. The report features detailed profiles of investigational therapies across both clinical and preclinical stages of development. It also evaluates HER2-negative breast cancer treatments based on therapy type, development phase, route of administration, and molecular classification. In addition, the report identifies and reviews inactive…
Marginal Zone Lymphoma Pipeline and Clinical Trial Analysis: 50+ Players, 50+ As …
DelveInsight's "Marginal Zone Lymphoma Pipeline Insight" report delivers an in-depth analysis of more than 50 companies and 50+ investigational drugs shaping the Marginal Zone Lymphoma (MZL) pipeline ecosystem. The report comprehensively outlines Marginal Zone Lymphoma drug profiles, spanning both clinical-stage and non-clinical development programs.
It further evaluates the Marginal Zone Lymphoma therapeutic landscape based on product classification, development phase, route of administration, and molecular category. Additionally, the report identifies and examines…
Non-Muscle Invasive Bladder Cancer Pipeline and Clinical Trial Analysis: 20+ Pla …
DelveInsight's "Non-Muscle Invasive Bladder Cancer Pipeline Insight" report delivers an in-depth analysis of more than 20 companies and over 22 investigational therapies shaping the NMIBC pipeline landscape.
The report features comprehensive profiles of pipeline candidates, spanning both clinical and preclinical stages of development.
It also presents a detailed therapeutic evaluation of NMIBC drugs based on product category, development phase, route of administration, and molecular classification.
In addition, the study sheds light on discontinued…
More Releases for Heart
Heart Healthy Foods and Supplements vs Heart Conditions
Heart conditions remain a major health concern worldwide, but the good news is that specific heart healthy foods and supplements can significantly improve cardiovascular health.
Scientific research has demonstrated that certain foods, nutrients and supplements support heart function, reduce inflammation, and lower the risk of heart disease.
Top Heart Healthy Foods
Fatty Fish - Salmon, mackerel, and sardines are rich in omega-3 fatty acids, which help lower blood pressure and reduce inflammation. A…
Centrifugal Heart Pumps Market | Abbott Laboratories, Abiomed, Berlin Heart, Car …
The global centrifugal heart pumps market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the centrifugal heart pumps market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
Heart disease and Heart Attacks - Kaffailham.gr
Καρδιολόγος Αθηνα - https://kaffailham.gr
When people talk about heart disease or heart attacks. The arteries that they are talking about are the arteries that actually provide blood to the heart. Remember the heart itself is a muscle. It itself needs oxygen. So you have these arteries right over here, the red tubes. Those are arteries. and then the blue ones are veins. They're taking the de-oxygenated blood away from the tissue…
Artificial Heart Implant Market May See a Big Move | Major Giants Jarvik Heart, …
The Latest survey report on Artificial Heart Implant Market sheds lights on changing dynamics of each of the subsegments of Industry. As the shift to value continues, Artificial Heart Implant organizations have the dual challenge of increasing interoperability to improve clinical performance and the patient experience. Some of the companies listed in the study from complete survey list are Medtronic, Boston Scientific, Abbott, Terumo, B.Braun, SynCardia, BiVACOR, CARMAT, ReinHeart TAH…
HEART PUMP DEVICES Market 2020 | SWOT Analysis By Top Players Abbott Laboratorie …
A detailed study on HEART PUMP DEVICES Market formulated by Brandessence Market Research, puts together a concise analysis of the growth factors impacting the current business scenario across assorted regions. Significant information pertaining to the industry's size, share, application, and statistics are also summed in the report in order to present an ensemble prediction. In addition, this report undertakes an accurate competitive analysis illustrating the status of market majors in…
Heart Pump Device Market - Potential Innovations 2025 | Terumo, Jarvik Heart
Heart Pump Device Market: Snapshot
Heart pump devices are essentially mechanical pumps playing the role of ventricular assist devices. These are surgically implanted and are used for temporarily supporting the functions of heart in people with weak heart or irregular blood flow. These devices are notably used as a bridge to cardiac transplantation for patients suffering with end stage heart failure. They can also be used in patients during and after…
